GlassScriptPhysician profile
Ryan M Harden
NPI 1295957116
$847.74
in general payments reported to CMS, 2019-2025
27 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.79 · 2020: $24.53 · 2021: $205 · 2022: $66.54 · 2023: $173 · 2024: $184 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $512.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $126.39 | 2023-2025 | Keveyis |
| Astrazeneca Pharmaceuticals LP | $118.41 | 2022-2025 | Airsupra, Breztri |
| Abbvie INC. | $60.01 | 2023-2025 | |
| Amgen INC. | $50.17 | 2020-2023 | Otezla, Repatha |
| Pfizer INC. | $48.79 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $48.58 | 2022-2024 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $48.03 | 2019-2021 | |
| Eisai INC. | $31.21 | 2021 | |
| Abiomed | $28.94 | 2025 | |
| Nestle Healthcare Nutrition INC. | $26.14 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $22.89 | 2021 | |
| Astellas Pharma US INC | $20.66 | 2025 | Veozah |
| Viatris Specialty LLC | $18.89 | 2025 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $16.97 | 2025 | |
| Novartis Pharmaceuticals Corporation | $16.51 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $15.78 | 2024 | Ingrezza |
| Circassia INC. | $15.76 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $14.96 | 2021 | |
| Horizon Therapeutics Plc | $14.36 | 2023 | Krystexxa |
| Ardelyx, INC. | $14.20 | 2024 | Ibsrela |
| Gilead Sciences, INC. | $13.47 | 2024 | |
| Aimmune Therapeutics, INC. | $13.42 | 2024 | |
| Morphosys, US INC. | $13.30 | 2021 | |
| Amarin Pharma, INC. | $13.13 | 2021 | |
| Incyte Corporation | $12.95 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.08 | 2021 | |
| Novo Nordisk INC | $11.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Harden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.